

company announcement

Trading in Novo Nordisk shares by board members, executives and associated persons

Bagsværd, Denmark, 1 February 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

The company's board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company's board members, executives and their associated persons.

Please find below a statement of such trading in shares issued by Novo Nordisk.

1	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person	Liselotte Sofie Hyeved						
2	Reason for the notification							
a)	Position/status	Member of the Board of Directors						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 0.00</td> <td>2,028 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 0.00	2,028 shares		
Price(s)	Volume(s)							
DKK 0.00	2,028 shares							
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	2,028 shares DKK 0.00						
e)	Date of the transaction	2024-01-31						
f)	Place of the transaction	Outside a trading venue						

1	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person	Liselotte Sofie Hyeled						
2	Reason for the notification							
a)	Position/status	Member of the Board of Directors						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 0.00</td> <td>2,042 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 0.00	2,042 shares		
Price(s)	Volume(s)							
DKK 0.00	2,042 shares							
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	2,042 shares DKK 0.00						
e)	Date of the transaction	2024-01-31						
f)	Place of the transaction	Outside a trading venue						

1	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person	Lars Fruergaard Jørgensen						
2	Reason for the notification							
a)	Position/status	President and CEO						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 0.00</td> <td>131,760 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 0.00	131,760 shares		
Price(s)	Volume(s)							
DKK 0.00	131,760 shares							
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	131,760 shares DKK 0.00						
e)	Date of the transaction	2024-01-31						
f)	Place of the transaction	Outside a trading venue						

1	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person	Lars Fruergaard Jørgensen						
2	Reason for the notification							
a)	Position/status	President and CEO						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 0.00</td> <td>149,422 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 0.00	149,422 shares		
Price(s)	Volume(s)							
DKK 0.00	149,422 shares							
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	149,422 shares DKK 0.00						
e)	Date of the transaction	2024-01-31						
f)	Place of the transaction	Outside a trading venue						

1	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person	Maziar Mike Doustdar						
2	Reason for the notification							
a)	Position/status	Executive Vice President						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 0.00</td> <td>41,488 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 0.00	41,488 shares		
Price(s)	Volume(s)							
DKK 0.00	41,488 shares							
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	41,488 shares DKK 0.00						
e)	Date of the transaction	2024-01-31						
f)	Place of the transaction	Outside a trading venue						

1	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person	Maziar Mike Doustdar						
2	Reason for the notification							
a)	Position/status	Executive Vice President						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 0.00</td> <td>48,791 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 0.00	48,791 shares		
Price(s)	Volume(s)							
DKK 0.00	48,791 shares							
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	48,791 shares DKK 0.00						
e)	Date of the transaction	2024-01-31						
f)	Place of the transaction	Outside a trading venue						

1	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person	Maziar Mike Doustdar						
2	Reason for the notification							
a)	Position/status	Executive Vice President						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Sale of shares						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 756.84</td> <td>2,166 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 756.84	2,166 shares		
Price(s)	Volume(s)							
DKK 756.84	2,166 shares							
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	2,166 shares DKK 756.84						
e)	Date of the transaction	2024-01-31						
f)	Place of the transaction	Nasdaq Copenhagen						

1	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person	Maziar Mike Doustdar						
2	Reason for the notification							
a)	Position/status	Executive Vice President						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Sale of shares						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 756.84</td> <td>2,548 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 756.84	2,548 shares		
Price(s)	Volume(s)							
DKK 756.84	2,548 shares							
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	2,548 shares DKK 756.84						
e)	Date of the transaction	2024-01-31						
f)	Place of the transaction	Nasdaq Copenhagen						

1	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person	Ludovic Helfgott						
2	Reason for the notification							
a)	Position/status	Executive Vice President						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 0.00</td> <td>37,346 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 0.00	37,346 shares		
Price(s)	Volume(s)							
DKK 0.00	37,346 shares							
d)	Aggregated information <ul style="list-style-type: none"> • Aggregated volume • Price 	37,346 shares DKK 0.00						
e)	Date of the transaction	2024-01-31						
f)	Place of the transaction	Outside a trading venue						

1	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person	Ludovic Helfgott						
2	Reason for the notification							
a)	Position/status	Executive Vice President						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 0.00</td> <td>36,664 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 0.00	36,664 shares		
Price(s)	Volume(s)							
DKK 0.00	36,664 shares							
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	36,664 shares DKK 0.00						
e)	Date of the transaction	2024-01-31						
f)	Place of the transaction	Outside a trading venue						

1	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person	Ludovic Helfgott						
2	Reason for the notification							
a)	Position/status	Executive Vice President						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Sale of shares						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 756.84</td> <td>11,620 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 756.84	11,620 shares		
Price(s)	Volume(s)							
DKK 756.84	11,620 shares							
d)	Aggregated information <ul style="list-style-type: none"> • Aggregated volume • Price 	11,620 shares DKK 756.84						
e)	Date of the transaction	2024-01-31						
f)	Place of the transaction	Nasdaq Copenhagen						

1	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person	Ludovic Helfgott						
2	Reason for the notification							
a)	Position/status	Executive Vice President						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Sale of shares						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 756.84</td> <td>11,407 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 756.84	11,407 shares		
Price(s)	Volume(s)							
DKK 756.84	11,407 shares							
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	11,407 shares DKK 756.84						
e)	Date of the transaction	2024-01-31						
f)	Place of the transaction	Nasdaq Copenhagen						

1	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person	Karsten Munk Knudsen						
2	Reason for the notification							
a)	Position/status	Executive Vice President						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 0.00</td> <td>41,254 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 0.00	41,254 shares		
Price(s)	Volume(s)							
DKK 0.00	41,254 shares							
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	41,254 shares DKK 0.00						
e)	Date of the transaction	2024-01-31						
f)	Place of the transaction	Outside a trading venue						

1	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person	Karsten Munk Knudsen						
2	Reason for the notification							
a)	Position/status	Executive Vice President						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 0.00</td> <td>43,402 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 0.00	43,402 shares		
Price(s)	Volume(s)							
DKK 0.00	43,402 shares							
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	43,402 shares DKK 0.00						
e)	Date of the transaction	2024-01-31						
f)	Place of the transaction	Outside a trading venue						

1	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person	Douglas Langa						
2	Reason for the notification							
a)	Position/status	Executive Vice President						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 0.00</td> <td>41,488 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 0.00	41,488 shares		
Price(s)	Volume(s)							
DKK 0.00	41,488 shares							
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	41,488 shares DKK 0.00						
e)	Date of the transaction	2024-01-31						
f)	Place of the transaction	Outside a trading venue						

1	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person	Douglas Langa						
2	Reason for the notification							
a)	Position/status	Executive Vice President						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 0.00</td> <td>39,755 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 0.00	39,755 shares		
Price(s)	Volume(s)							
DKK 0.00	39,755 shares							
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	39,755 shares DKK 0.00						
e)	Date of the transaction	2024-01-31						
f)	Place of the transaction	Outside a trading venue						

1	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person	Douglas Langa						
2	Reason for the notification							
a)	Position/status	Executive Vice President						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Sale of shares						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 756.84</td> <td>22,027 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 756.84	22,027 shares		
Price(s)	Volume(s)							
DKK 756.84	22,027 shares							
d)	Aggregated information <ul style="list-style-type: none"> • Aggregated volume • Price 	22,027 shares DKK 756.84						
e)	Date of the transaction	2024-01-31						
f)	Place of the transaction	Nasdaq Copenhagen						

1	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person	Douglas Langa						
2	Reason for the notification							
a)	Position/status	Executive Vice President						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Sale of shares						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 756.84</td> <td>19,878 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 756.84	19,878 shares		
Price(s)	Volume(s)							
DKK 756.84	19,878 shares							
d)	Aggregated information <ul style="list-style-type: none"> • Aggregated volume • Price 	19,878 shares DKK 756.84						
e)	Date of the transaction	2024-01-31						
f)	Place of the transaction	Nasdaq Copenhagen						

1	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person	Douglas Langa						
2	Reason for the notification							
a)	Position/status	Executive Vice President, head of North America Operations						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	ADRs NVO						
b)	Nature of the transaction	Purchase of ADRs						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 1,092.25</td> <td>16.31 ADRs</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 1,092.25	16.31 ADRs		
Price(s)	Volume(s)							
DKK 1,092.25	16.31 ADRs							
d)	Aggregated information <ul style="list-style-type: none"> • Aggregated volume • Price 	16.31 ADRs DKK 1,092.25						
e)	Date of the transaction	2023-04-10						
f)	Place of the transaction	New York Stock Exchange						

1	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person	Douglas Langa						
2	Reason for the notification							
a)	Position/status	Executive Vice President, head of North America Operations						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	ADRs NVO						
b)	Nature of the transaction	Purchase of ADRs						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 1,275.49</td> <td>10.42 ADRs</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 1,275.49	10.42 ADRs		
Price(s)	Volume(s)							
DKK 1,275.49	10.42 ADRs							
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	10.42 ADRs DKK 1,275.49						
e)	Date of the transaction	2023-09-01						
f)	Place of the transaction	New York Stock Exchange						

1	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person	Martin Holst Lange						
2	Reason for the notification							
a)	Position/status	Executive Vice President						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 0.00</td> <td>16,780 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 0.00	16,780 shares		
Price(s)	Volume(s)							
DKK 0.00	16,780 shares							
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	16,780 shares DKK 0.00						
e)	Date of the transaction	2024-01-31						
f)	Place of the transaction	Outside a trading venue						

1	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person	Martin Holst Lange						
2	Reason for the notification							
a)	Position/status	Executive Vice President						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 0.00</td> <td>33,600 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 0.00	33,600 shares		
Price(s)	Volume(s)							
DKK 0.00	33,600 shares							
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	33,600 shares DKK 0.00						
e)	Date of the transaction	2024-01-31						
f)	Place of the transaction	Outside a trading venue						

1	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person	Tania Sabroe						
2	Reason for the notification							
a)	Position/status	Executive Vice President						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 0.00</td> <td>7,763 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 0.00	7,763 shares		
Price(s)	Volume(s)							
DKK 0.00	7,763 shares							
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	7,763 shares DKK 0.00						
e)	Date of the transaction	2024-01-31						
f)	Place of the transaction	Outside a trading venue						

1	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person	Tania Sabroe						
2	Reason for the notification							
a)	Position/status	Executive Vice President						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 0.00</td> <td>13,220 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 0.00	13,220 shares		
Price(s)	Volume(s)							
DKK 0.00	13,220 shares							
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	13,220 shares DKK 0.00						
e)	Date of the transaction	2024-01-31						
f)	Place of the transaction	Outside a trading venue						

1	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person	Tania Sabroe						
2	Reason for the notification							
a)	Position/status	Executive Vice President						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Sale of shares						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 756.84</td> <td>413 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 756.84	413 shares		
Price(s)	Volume(s)							
DKK 756.84	413 shares							
d)	Aggregated information <ul style="list-style-type: none"> • Aggregated volume • Price 	413 shares DKK 756.84						
e)	Date of the transaction	2024-01-31						
f)	Place of the transaction	Nasdaq Copenhagen						

1	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person	Tania Sabroe						
2	Reason for the notification							
a)	Position/status	Executive Vice President						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Sale of shares						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 756.84</td> <td>702 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 756.84	702 shares		
Price(s)	Volume(s)							
DKK 756.84	702 shares							
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	702 shares DKK 756.84						
e)	Date of the transaction	2024-01-31						
f)	Place of the transaction	Nasdaq Copenhagen						

1	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person	Marcus Schindler						
2	Reason for the notification							
a)	Position/status	Executive Vice President						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 0.00</td> <td>16,780 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 0.00	16,780 shares		
Price(s)	Volume(s)							
DKK 0.00	16,780 shares							
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	16,780 shares DKK 0.00						
e)	Date of the transaction	2024-01-31						
f)	Place of the transaction	Outside a trading venue						

1	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person	Marcus Schindler						
2	Reason for the notification							
a)	Position/status	Executive Vice President						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 0.00</td> <td>33,600 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 0.00	33,600 shares		
Price(s)	Volume(s)							
DKK 0.00	33,600 shares							
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	33,600 shares DKK 0.00						
e)	Date of the transaction	2024-01-31						
f)	Place of the transaction	Outside a trading venue						

1	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person	Camilla Sylvest						
2	Reason for the notification							
a)	Position/status	Executive Vice President						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 0.00</td> <td>41,254 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 0.00	41,254 shares		
Price(s)	Volume(s)							
DKK 0.00	41,254 shares							
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	41,254 shares DKK 0.00						
e)	Date of the transaction	2024-01-31						
f)	Place of the transaction	Outside a trading venue						

1	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person	Camilla Sylvest						
2	Reason for the notification							
a)	Position/status	Executive Vice President						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 0.00</td> <td>43,402 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 0.00	43,402 shares		
Price(s)	Volume(s)							
DKK 0.00	43,402 shares							
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	43,402 shares DKK 0.00						
e)	Date of the transaction	2024-01-31						
f)	Place of the transaction	Outside a trading venue						

1	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person	Henrik Ehlers Wulff						
2	Reason for the notification							
a)	Position/status	Executive Vice President						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 0.00</td> <td>43,563 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 0.00	43,563 shares		
Price(s)	Volume(s)							
DKK 0.00	43,563 shares							
d)	Aggregated information <ul style="list-style-type: none"> • Aggregated volume • Price 	43,563 shares DKK 0.00						
e)	Date of the transaction	2024-01-31						
f)	Place of the transaction	Outside a trading venue						

1	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person	Henrik Ehlers Wulff						
2	Reason for the notification							
a)	Position/status	Executive Vice President						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 0.00</td> <td>45,834 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 0.00	45,834 shares		
Price(s)	Volume(s)							
DKK 0.00	45,834 shares							
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	45,834 shares DKK 0.00						
e)	Date of the transaction	2024-01-31						
f)	Place of the transaction	Outside a trading venue						

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 63,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit [novonordisk.com](https://www.novonordisk.com), [Facebook](#), [Instagram](#), [X](#), [LinkedIn](#) and [YouTube](#).

Contacts for further information

Media:

Ambre James-Brown

+45 3079 9289

abmo@novonordisk.com

Elizabeth DeLuca (US)

+1 609 580 9868

edel@novonordisk.com

Investors:

Daniel Muusmann Bohsen

+45 3075 2175

dabo@novonordisk.com

Frederik Taylor Pitter

+45 3075 8259

fpitr@novonordisk.com

David Heiberg Landsted

+45 3077 6915

dhel@novonordisk.com

Mark Joseph Root (US)

+1 848 213 3219

mjhr@novonordisk.com

Sina Meyer

+45 3079 6656

azey@novonordisk.com